Androgen Receptor in Cancers: Not Only Prostate

Dear Colleagues,

The androgen receptor belongs to the sex steroid receptor family and is commonly known as a transcription factor that is directly involved in prostate cancer (PC) progression. Recent advances have not only discovered that AR influences PC behavior by controlling the rapid activation of different signaling transduction pathways, but also that this steroid receptor affects the pathogenesis and advancement of cancer in a plethora of other organs in addition to the prostate.  The role of AR in breast cancer is now better known, especially in the most aggressive subtype triple negative breast cancer (TNBC); furthermore, it is also clear that AR can act upon the development and progression of non-hormone related cancers such as gastroesophageal and lung cancers or melanoma. These tumors are known as gender-related cancers because their incidence and mortality are unequal between men and women, displaying the highest number in the former.  The study and understanding of mechanisms influencing the differences between the two sexes could be useful to develop preventive screening or therapeutic strategies to limit the onset of these tumors.

This Special Issue aims to increase the knowledge about the role of the androgen receptor in all cancers that are not usually dependent on androgens in the same way as for prostate cancer. All original articles and reviews describing AR action in cancers except prostate are welcome.

Research areas may include (but are not limited to) the following:

• AR in cancer;
• AR in the cancer microenvironment;
• AR in exosomes;
• AR in cancer therapy.

I look forward to receiving your contributions.

Dr. Pia Giovannelli
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.